Parker Waichman LLP Takes On Novo Nordisk Over Ozempic-Linked Eye Injury Cases

Parker Waichman LLP, a prominent law firm in the arena of defective drugs and devices, has recently taken significant legal action against Novo Nordisk. The firm has filed a lawsuit in the Superior Court of New Jersey, Middlesex County, representing a New Jersey resident diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) after using Ozempic, a medication designed to aid weight loss as well as manage Type 2 diabetes.

The case marks one of the earliest legal actions focusing on serious eye injuries purportedly linked to the active ingredient, semaglutide, found in Ozempic. NAION is a severe condition that can lead to permanent vision loss, caused by interrupted blood flow to the optic nerve. This alarming diagnosis is echoing among patients who have consumed the medication, with reports of sudden blindness and optic nerve damage emerging frequently.

The Disturbing Connection

Recent studies have raised crucial concerns about the safety of semaglutide, originally regarded as a breakthrough treatment for diabetes and weight management. Research published in JAMA Ophthalmology in 2025 reviewed a group of nine patients who developed optic nerve issues after using GLP-1 receptor agonists like Ozempic. The findings revealed that many of these patients displayed symptoms reminiscent of NAION.

Harvard's Mass Eye and Ear Institute further emphasized these dangers, revealing that diabetic patients using semaglutide were four times more likely to develop NAION, while those taking the medication for weight loss faced a staggering sevenfold increased risk.

Despite the mounting evidence presented by various reputable institutions, Novo Nordisk appears to be downplaying the potential risks associated with their drugs. They have yet to adequately warn consumers and healthcare providers about the risk of irrevocable blindness linked to their medication.

Fighting for Justice

Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP, has been vocal regarding the firm’s commitment to these cases. “NAION represents a devastating and permanent eye injury. Studies have shown a statistically significant link between semaglutide and NAION. Unfortunately, Novo Nordisk fails to acknowledge the reality of this situation, withholding vital information from consumers and medical professionals,” Goldstein stated.

The firm is extending its support to victims throughout the nation who have experienced vision loss, blindness, or serious optic nerve injuries following the administration of Ozempic or Wegovy. Such individuals could be eligible for compensation covering medical costs, lost wages, emotional distress, and other damages.

Free Legal Consultations Available

Parker Waichman LLP offers free consultations for anyone affected by optic nerve damage related to these drugs. Victims or their families can contact the firm for a no-obligation case evaluation. Parker Waichman LLP emphasizes the importance of understanding one’s legal rights and pursuing justice in these troubling circumstances.

For those seeking assistance, a quick phone call to 1-800-YOUR-LAWYER (1-800-968-7529) or a visit to YourLawyer.com could be a vital first step.

About Parker Waichman LLP

Parker Waichman LLP is a nationally recognized law firm committed to advocating for victims affected by defective medications, dangerous consumer products, and corporate negligence. With a proven history of holding pharmaceutical companies accountable, they have successfully recovered billions in settlements and verdicts for clients harmed by such negligence.